Cure8 research brief
This method helps translate complex paired microbiome and metabolome data into coherent functional modules; that could clarify microbial metabolic alterations in IBD or IBS and guide future biomarker or mechanistic studies.
Researchers working on the gut microbiome and metabolomics, translational scientists studying IBD or IBS mechanisms, computational biologists, and clinicians interested in microbiome-derived biomarkers.
MAAMOUL is a knowledge-guided R package that maps association scores from genes and metabolites onto a global microbial metabolic network and extracts custom modules enriched for changes, instead of relying on fixed pathway definitions.
The authors applied it to IBD and IBS datasets and report modules not found by conventional pathway-level analyses, suggesting it can uncover coordinated multi-omic shifts.
The results are framed as a computational discovery tool: the paper describes detected metabolic modules (examples include disrupted sulfur and aromatic amino-acid metabolism and increased nucleotide salvage in IBD) but does not report clinical interventions or patient-level outcomes.
The software is available on GitHub for researchers who want to apply the approach to their own paired metagenomic–metabolomic datasets.
Structured content depth is abstract: the supplied text is an abstract describing the method and example applications. Findings are computational and hypothesis-generating; follow-up experimental or clinical validation would be needed before clinical use.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: NIH HHS - U19AG057377; Safra Center for Bioinformatics at Tel-Aviv University; Israel Science Foundation - 2266/25; Raymond and Beverly Sackler Chair in Bioinformatics at Tel Aviv University
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
The review connects microbiome-targeted therapies (diet, probiotics, FMT, antibiotics, and newer approaches) to mechanisms relevant to IBD and systemic health, highlighting why these strategies are of interest to...
IBD and other lower-GI disorders may benefit from oral hydrogel platforms that improve local drug delivery while deliberately engaging the gut microbiota. Understanding this research direction helps patients and...
